The Latest Cardiac and Vascular News
SCHAFFHAUSEN, Switzerland, Aug. 16, 2021 /PRNewswire/ — Occlutech Holding AG (“Occlutech”), one of the world´s leading providers of minimally invasive structural heart disease devices, announces the conditional U.S. Food and Drug Administration (“FDA”) approval of its Investigational Device Exemption (“IDE”) application to conduct a […]
SCHAFFHAUSEN, Switzerland, June 1, 2021 /PRNewswire/ — Occlutech AG (“Occlutech” or the “Company”) today announces that the planned recruitment of 180 patients has been reached in the Company’s trial in China for its ASD Occluder. The Occlutech ASD Occluder is used in the treatment of Atrial […]
Medical device company Occlutech Holding AG, one of the world´s leading providers of minimally invasive structural heart disease devices, announces the election of four new members to the board SCHAFFHAUSEN, Switzerland, May 3, 2021 /PRNewswire/ — Occlutech Holding AG (“Occlutech”) today announces that […]
SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ — Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is […]
SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ — Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH). PAH […]
SCHAFFHAUSEN, Switzerland, Sept. 6, 2019 /PRNewswire/ — Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt […]
NEWS PROVIDED BY – Occlutech – 05 Apr, 2017, 07:00 ET SCHAFFHAUSEN, Switzerland, April 5, 2017 /PRNewswire/ — Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its […]
